Cybin Receives Expedited Review FDA Breakthrough | Trade To Black
Cybin Receives Expedited Review FDA Breakthrough | Trade To Black
In this episode of the Trade to Black Podcast, we sit down with Doug Drysdale, Chief Executive Officer of Cybin, to discuss the recent milestones and future prospects of their novel psychedelic molecule, CYB003.
#Cybin #Cybinstock #thedalesreport
Key topics covered in this interview:
– FDA’s Breakthrough Therapy Designation
– Phase 2 Trial…
source
Reviews
0 %
I enjoy seeing and hearing Doug and all the accomplishments he is having. If I didn’t know any better it sounds like everything they touch is being fast tracked 🙂
Disappointed about the dilution but without it there is no other way as these trials and studies are a cash burning machine.
The later half of this year will be interesting.
as an investor in the sector the share-outstanding they have compare to other company in the same field ( the have 410 million compare to the 91 million of compass and 41 of mind medicine) is a big red flag
TY! 🙏🏽
hello, good interview.
when is the rs news coming and what will the ratio be?
thanks
great interview ! I do not know why the stock price does not move . Ill just buy more
Is he referring to the US FDA, Canada FDA or both?
Go for it!
Are any Numinous clinics part of the trials?
Thrilled…blessings…m
This stock gonna blow 💪
Their addressable market is larger than the smart phone market.
Thanks for the update! 🚀
Will they be using Numinus clinics to host these trials ?